Nemvaleukin Alfa Plus Pembrolizumab Gets Fast Track Status for Platinum-Resistant Ovarian Cancer

Article

The FDA has granted a fast track designation to the interleukin-2 variant immunotherapy nemvaleukin alfa for use in combination with pembrolizumab in the treatment of patients with platinum-resistant ovarian cancer.

Craig Hopkinson, MD

Craig Hopkinson, MD

The FDA has granted a fast track designation to the interleukin-2 (IL-2) variant immunotherapy nemvaleukin alfa (nemvaleukin) in combination with pembrolizumab (Keytruda) for the treatment of patients with platinum-resistant ovarian cancer.1

The investigational engineered fusion protein is composed of modified IL-2 and the high affinity IL-2 alpha receptor chain, which preferentially expands tumor-killing immune cells and avoids the activation of immunosuppression cells through selective binding to the intermediate-affinity IL-2 receptor complex. The selectivity of the agent is hypothesized to leverage the antitumor effects of existing IL-2 therapy and diminish select limitations.

Nemvaleukin plus pembrolizumab will be compared with investigator’s choice of chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, as part of the global, open-label, phase 3 ARTISTRY-7 trial (NCT05092360), which was initiated on October 26, 2021.2 Additional nemvaleukin and pembrolizumab monotherapy arms will also be evaluated.

“The fast track designation in platinum-resistant ovarian cancer highlights the potential clinical utility of nemvaleukin in combination with pembrolizumab in this difficult-to-treat disease for which there is no approved immunotherapy and there remains significant need for new treatment options,” Craig Hopkinson, MD, chief medical officer and executive vice president of Research & Development at Alkermes plc, stated in a press release. “We are excited to initiate…[the] ARTISTRY-7 phase 3 trial in platinum-resistant ovarian cancer, as we advance nemvaleukin toward potential registration and seek to help patients living with this disease.”

To be eligible for enrollment to ARTISTRY-7, patients need to be at least 18 years of age, have platinum-resistant or -refractory disease, have received at least 1 previous line of systemic therapy in the platinum-sensitive setting, have at least 1 measurable lesion per RECIST v1.1 criteria, and be willing to undergo a pretreatment tumor biopsy.3

If patients had primary platinum-refractory disease or primary platinum resistance, a histologically confirmed diagnosis of epithelial ovarian carcinoma with mucinous or carcinosarcoma subtype, or a nonepithelial tumor, they will be excluded. Other exclusion criteria include having previously received IL-2–based or IL-15–based cytokine therapy and prior exposure to any anti–PD-1/PD-L1 therapy.

Participants will be centrally allocated in a randomized 3:1:1:3 fashion to receive either nemvaleukin and pembrolizumab, pembrolizumab monotherapy, nemvaleukin monotherapy, or investigator’s choice of chemotherapy, which could include 1 of the following: pegylated liposomal doxorubicin (PLD), paclitaxel, topotecan, or gemcitabine.

Nemvaleukin will be given at a daily dose of 6 µg/kg on days 1 through 5 of 21-day treatment cycles. Pembrolizumab will be administered at a dose of 200 mg on day 1 of each 21-day cycle. PLD will be given at 40 mg/m2 on day 1 of 28-day cycles; paclitaxel will be given at 80 mg/m2 on days 1, 8, 15, and 22 of 28-day cycles; topotecan will be given at 4 mg/m2 on days 1, 8, and 15 of 28-day cycles; and gemcitabine will be given at 1000 mg/m2 on days 1 and 8 if 21-day cycles.

The primary end point of the trial is investigator-assessed progression-free survival based on RECIST v1.1 criteria. Additional end points include objective response rate, overall survival, disease control rate, duration of response, time to response, cancer antigen-125 response, pharmacokinetics, pharmacodynamics, and safety.

Investigators plan to enroll approximately 376 patients to the trial.

“The initiation of our phase 3 study of nemvaleukin in platinum-resistant ovarian cancer is an important milestone for the nemvaleukin clinical development program and reflects our commitment to focusing on the high unmet need of patients living with difficult-to-treat cancers such as platinum-resistant ovarian cancer,” Hopkinson stated in a press release. “ARTISTRY-7 is designed to build upon the durable and deepening responses observed in heavily pretreated patients with platinum-resistant ovarian cancer in the ongoing ARTISTRY-1 trial [NCT02799095]. We look forward to sharing updates from ARTISTRY-7 as the study progresses and as we advance toward potential registration.”

Previously, in August 2021, the FDA granted a fast track designation to nemvaleukin for the treatment of patients with mucosal melanoma.4 In the phase 2 ARTISTRY-6 trial (NCT04830124), investigators are evaluating the antitumor activity, safety, and tolerability of nemvaleukin in this patient population. The study also includes a cohort of patient with advanced cutaneous melanoma who will receive subcutaneous nemvaleukin with the intent to establish single agent proof-of-concept with the latter dosing.5

References

  1. Alkermes receives FDA fast track designation for nemvaleukin alfa in combination with pembrolizumab for the treatment of platinum-resistant ovarian cancer. News release. Alkermes plc. October 25, 2021. Accessed October 26, 2021. https://bit.ly/3ExZ6Th
  2. Alkermes initiates ARTISTRY-7 phase 3 trial of nemvaleukin alfa in patients with platinum-resistant ovarian cancer. News release. Alkermes plc. October 26, 2021. Accessed October 26, 2021. https://prn.to/3pEvLC9
  3. Phase 3 study of nemvaleukin alfa in combination with pembrolizumab (ARTISTRY-7). ClinicalTrials.gov. Updated October 25, 2021. Accessed October 26, 2021. https://www.clinicaltrials.gov/ct2/show/NCT05092360
  4. Alkermes receives FDA fast track designation for nemvaleukin alfa for the treatment of mucosal melanoma. News release. Alkermes plc. August 2, 2021. Accessed October 26, 2021. https://bit.ly/2WMtb0G
  5. Alkermes initiates ARTISTRY-6 trial of nemvaleukin alfa monotherapy in patients with melanoma. News release. Alkermes plc. April 27, 2021. Accessed October 26, 2021. https://bit.ly/3xf9Ql7
Related Videos
Robert DeBernardo, MD, section head, Obstetrics and Gynecology, Women’s Health Institute, Cleveland Clinic
Susan Marie Lang, MD
Gabriella Smith, MD
Sarah Crafton, MD
Robert DeBernardo, MD
Gabriella Smith, MD
Susan Marie Lang, MD
Sarah Crafton, MD
Eirwen M. Miller, MD
Eirwen M. Miller, MD